Page 59 - ARNM-3-3

Advances in Radiotherapy
& Nuclear Medicine LuPSMA response patterns on PSMA PET

5. Conclusion ACTRN12618001073291) and all participants provided
signed, written, informed consent.
The TLW is a feasible method of measuring heterogeneous
177
treatment responses to Lu-PSMA-617. This study showed Consent for publication
that the TLW can provide a more granular characterization of
progressive lesions and found that the overall TLW response All participants provided signed, written, informed
category was prognostic for OS. Further work is warranted consent for publication.
to validate the TLW in larger, independent cohorts. Availability of data

Acknowledgments Data supporting the findings of this study are available
We ould like to thank the patients and the clinical trials from the corresponding author on reasonable request.
teams at the Department of Theranostics and Nuclear Further disclosure
Medicine, and the Kinghorn Cancer Centre, St Vincent’s
Hospital, for their support. Part of or the entire set of findings has been presented at
the ASCO Genitourinary Cancers Symposium 2022. The
Funding meeting abstract can be accessed by searching the doi

The investigator-initiated study was sponsored by St (10.1200/JCO.2022.40.6_suppl.166).
Vincent’s Hospital and supported by a Cancer Institute References
NSW prostate translational research grant. Noxopharm
Limited provided funding for the drug and PET scans, 1. Hofman MS, Emmett L, Sandhu SK, et al. 177Lu-PSMA-617
whereas AAA/Novartis provided the PSMA-617 ligand. versus cabazitaxel in patients with metastatic castration-
resistant prostate cancer (TheraP): a randomised, open-
Conflict of interest label, phase 2 trial. Lancet. 2021;397(10276):797-804.
Louise Emmett holds an advisory position at Clarity doi: 10.1016/S0140-6736(21)00237-3
Pharmaceuticals and receives trial support from Novartis 2. Sartor O, De Bono J, Chi KN, et al. Lutetium-177-PSMA-617
and Astellas and grant funding from the St Vincent’s Clinic for metastatic castration-resistant prostate cancer. N Engl J
Foundation. Anthony M. Joshua holds an advisory position Med. 2021;385(12):1091-1103.
at Noxopharm Limited and receives institutional research doi: 10.1056/NEJMoa2107322
funding from Novartis. Remy Niman and Peter Wilson are
salaried employees of MIM Software Inc. All other authors 3. Hofman MS, Violet J, Hicks RJ, et al. [177 Lu]-PSMA-617
declare no relevant conflicts of interest. radionuclide treatment in patients with metastatic
castration-resistant prostate cancer (LuPSMA trial):
Author contributions A single-centre, single-arm, phase 2 study. Lancet Oncol.
2018;19(6):825-833.
Conceptualization: Sarennya Pathmanandavel, Louise doi: 10.1016/s1470-2045(18)30198-0
Emmett
Formal analysis: Sarennya Pathmanandavel, Andrew J. 4. Gafita A, Rauscher I, Weber M, et al. Novel framework for
Martin, Louise Emmett treatment response evaluation using PSMA PET/CT in
Investigation: Sarennya Pathmanandavel, Megan patients with metastatic castration-resistant prostate cancer
Crumbaker, Andrew Nguyen, Andrew O. Yam, Maria (RECIP 1.0): An international multicenter study. J Nucl Med.
2022;63:1651-1658.
Ayers, Shikha Sharma, Peter Eu, Anthony M. Joshua
Methodology: Louise Emmett, Andrew J. Martin, Martin R. doi: 10.2967/jnumed.121.263072
Stockler 5. Grubmuller B, Senn D, Kramer G, et al. Response assessment
Software: Remy Niman, Peter Wilson using 68 Ga-PSMA ligand PET in patients undergoing
Supervision: Louise Emmett, Andrew J. Martin, Martin R. 177 Lu-PSMA radioligand therapy for metastatic castration-
Stockler resistant prostate cancer. Eur J Nucl Med Mol Imaging.
Writing–original draft: Sarennya Pathmanandavel 2019;46(5):1063-1072.
Writing–review & editing: Louise Emmett, Andrew J. doi: 10.1007/s00259-018-4236-4
Martin, Martin R. Stockler
6. Crumbaker M, Pathmanandavel S, Yam AO, et al.
177
Ethics approval and consent to participate Phase I/II trial of the combination of lutetium prostate
specific membrane antigen 617 and idronoxil (NOX66) in
St Vincent’s Hospital Institutional Review Board men with end-stage metastatic castration-resistant prostate
approved the study protocol (HREC/17/SVH/19 cancer (LuPIN). Eur Urol Oncol. 2020;4:963-970.

Volume 3 Issue 3 (2025) 51 doi: 10.36922/ARNM025110011